Matthew Korenberg

2016

In 2016, Matthew Korenberg earned a total compensation of $2M as Vice President, Finance and Chief Financial Officer at Ligand Pharmaceuticals, a 30% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$118,500
Option Awards$797,704
Salary$378,750
Stock Awards$664,015
Other$7,872
Total$1,966,841

Korenberg received $797.7K in option awards, accounting for 41% of the total pay in 2016.

Korenberg also received $118.5K in non-equity incentive plan, $378.8K in salary, $664K in stock awards and $7.9K in other compensation.

Rankings

In 2016, Matthew Korenberg's compensation ranked 4,961st out of 14,075 executives tracked by ExecPay. In other words, Korenberg earned more than 64.8% of executives.

ClassificationRankingPercentile
All
4,961
out of 14,075
65th
Division
Manufacturing
1,774
out of 5,486
68th
Major group
Chemicals And Allied Products
561
out of 1,900
71st
Industry group
Drugs
417
out of 1,543
73rd
Industry
Pharmaceutical Preparations
332
out of 1,173
72nd
Source: SEC filing on April 14, 2017.

Korenberg's colleagues

We found three more compensation records of executives who worked with Matthew Korenberg at Ligand Pharmaceuticals in 2016.

2016

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2016

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2016

Charles Berkman

Ligand Pharmaceuticals

General Counsel

News

You may also like